Discover how physiotherapist Julie Allen tackles cancer fatigue and lymphoma, enhancing the quality of life and survival for blood cancer patients.
For Dr Sun Loo, being part of an innovative clinical trial is a perfect fit. It furthers research into her field of interest – measurable residual disease (MRD), and the blood cancer she is passionate about – acute myeloid leukaemia (AML).
Leukaemia researcher, Professor Andrew Wei hopes that clinical trials in the future will be routinely based on a new strategy of targeting measurable residual disease (MRD), commencing patients on treatment before clinical relapse.
Professor Daniel Tenen, who has devoted his research career to searching for a cure for cancer, has found an “ideal target”. It’s a gene called SALL4.
Carmel Woodrow has been in the field of nursing for over 40 years, with 30 of those years spent in haematology. Now working as a Clinical Nurse Consultant, Carmel focuses mainly on myeloma and amyloidosis patients.
When talking to her patients, clinical haematologist and researcher Associate Professor Nada Hamad always considers their eligibility for a clinical trial.
“Music is very much part of our lives” and that's why it's such a useful and effective tool in therapy, according to Tasmanian registered music therapist, Dr Stephanie Thompson.
When Julie Allen was diagnosed with lymphoma as a young professional mum, she thought she'd go straight back to work after treatment. But afterwards she literally felt “stripped bare”.
More than 80% of children newly diagnosed with acute lymphoblastic leukaemia (ALL) are successfully treated today – an achievement deemed by Dr Michael Osborn as “one of the true success stories of modern medicine”.
